Vincerx Pharma, Inc. (VINC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Vincerx Pharma, Inc. (VINC) is up 1.6% since the beginning of the year. At $0 per share, VINC is trading 82.8% below its 52-week high of $0. Investors who bought $1,000 worth of VINC shares 5 years ago would now be looking at an investment worth $0.

Vincerx Pharma, Inc. (VINC) has returned 1.60% so far this year and -74.08% over the past 12 months.

Based on dividend-adjusted daily data since May 27, 2020, VINC's average daily return is -0.24%, while the average monthly return is -2.72%.

Historically, 38% of months were positive and 62% were negative. The best month was Feb 2024 with a return of +186.3%, while the worst month was Apr 2025 at -90.1%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 12 months.

On a daily basis, VINC closed higher 41% of trading days. The best single day was Nov 17, 2025 with a return of +98.0%, while the worst single day was Oct 30, 2025 at -84.4%.

Vincerx Pharma, Inc. has an annualized alpha of -47.43%, beta of 0.29, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since May 28, 2020.

• This stock participated in 273.21% of S&P 500 Index downside but only -74.13% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.29 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

VINC ranks 32 for risk / return — below 32% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Vincerx Pharma, Inc. (VINC) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Vincerx Pharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Vincerx Pharma, Inc. was 100.00%, occurring on Oct 30, 2025. The portfolio has not yet recovered.

The current Vincerx Pharma, Inc. drawdown is 100.00%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Vincerx Pharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Vincerx Pharma, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.